ReP USP - Resultado da busca

Artigo de periodico-carta/editorial
Lung Cancer in Brazil [Editorial] (2020)
Mathias, Clarissa; Prado, Gustavo Faibischew; Mascarenhas, Eldsamira; Ugalde, Paula Antonia; Gelatti, Ana Carolina Zimmer; Carvalho, Elizangela Santos; Faroni, Lilian Dantonino; Oliveira, Ricardo; Lima, Vladmir Claudio Cordeiro de; Castro Junior, Gilberto de
Fonte: Journal of thoracic oncology. Unidade: FM
Assuntos: NEOPLASIAS PULMONARES, BRASIL
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
MATHIAS, Clarissa et al. Lung Cancer in Brazil [Editorial]. Journal of thoracic oncology. New York: Faculdade de Medicina, Universidade de São Paulo. Disponível em: https://doi.org/10.1016/j.jtho.2019.07.028. Acesso em: 15 jun. 2025. , 2020
APA
Mathias, C., Prado, G. F., Mascarenhas, E., Ugalde, P. A., Gelatti, A. C. Z., Carvalho, E. S., et al. (2020). Lung Cancer in Brazil [Editorial]. Journal of thoracic oncology. New York: Faculdade de Medicina, Universidade de São Paulo. doi:10.1016/j.jtho.2019.07.028
NLM
Mathias C, Prado GF, Mascarenhas E, Ugalde PA, Gelatti ACZ, Carvalho ES, Faroni LD, Oliveira R, Lima VCC de, Castro Junior G de. Lung Cancer in Brazil [Editorial] [Internet]. Journal of thoracic oncology. 2020 ; 15( 2): 170-175.[citado 2025 jun. 15 ] Available from: https://doi.org/10.1016/j.jtho.2019.07.028
Vancouver
Mathias C, Prado GF, Mascarenhas E, Ugalde PA, Gelatti ACZ, Carvalho ES, Faroni LD, Oliveira R, Lima VCC de, Castro Junior G de. Lung Cancer in Brazil [Editorial] [Internet]. Journal of thoracic oncology. 2020 ; 15( 2): 170-175.[citado 2025 jun. 15 ] Available from: https://doi.org/10.1016/j.jtho.2019.07.028
Artigo de periodico
Health-related quality of life in KEYNOTE-010: a phase II/III study of Pembrolizumab versus Docetaxel in patients with previously treated advanced, programmed death ligand 1-Expressing NSCLC (2019)
Barlesi, Fabrice; Garon, Edward B; Kim, Dong-Wan; Felip, Enriqueta; Han, Ji-Youn; Kim, Joo-Hang; Ahn, Myung-Ju; Fidler, Mary Jo; Gubens, Matthew A.; Castro Junior, Gilberto de
Fonte: Journal of thoracic oncology. Unidade: FM
Assuntos: NEOPLASIAS PULMONARES, QUIMIOTERAPIA, QUALIDADE DE VIDA, IMUNOHISTOQUÍMICA, ANTINEOPLÁSICOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
BARLESI, Fabrice et al. Health-related quality of life in KEYNOTE-010: a phase II/III study of Pembrolizumab versus Docetaxel in patients with previously treated advanced, programmed death ligand 1-Expressing NSCLC. Journal of thoracic oncology, v. 14, n. 5, p. 793-801, 2019Tradução . . Disponível em: https://doi.org/10.1016/j.jtho.2019.01.016. Acesso em: 15 jun. 2025.
APA
Barlesi, F., Garon, E. B., Kim, D. -W., Felip, E., Han, J. -Y., Kim, J. -H., et al. (2019). Health-related quality of life in KEYNOTE-010: a phase II/III study of Pembrolizumab versus Docetaxel in patients with previously treated advanced, programmed death ligand 1-Expressing NSCLC. Journal of thoracic oncology, 14( 5), 793-801. doi:10.1016/j.jtho.2019.01.016
NLM
Barlesi F, Garon EB, Kim D-W, Felip E, Han J-Y, Kim J-H, Ahn M-J, Fidler MJ, Gubens MA, Castro Junior G de. Health-related quality of life in KEYNOTE-010: a phase II/III study of Pembrolizumab versus Docetaxel in patients with previously treated advanced, programmed death ligand 1-Expressing NSCLC [Internet]. Journal of thoracic oncology. 2019 ; 14( 5): 793-801.[citado 2025 jun. 15 ] Available from: https://doi.org/10.1016/j.jtho.2019.01.016
Vancouver
Barlesi F, Garon EB, Kim D-W, Felip E, Han J-Y, Kim J-H, Ahn M-J, Fidler MJ, Gubens MA, Castro Junior G de. Health-related quality of life in KEYNOTE-010: a phase II/III study of Pembrolizumab versus Docetaxel in patients with previously treated advanced, programmed death ligand 1-Expressing NSCLC [Internet]. Journal of thoracic oncology. 2019 ; 14( 5): 793-801.[citado 2025 jun. 15 ] Available from: https://doi.org/10.1016/j.jtho.2019.01.016
Artigo de periodico
Efficacy and safety of ceritinib (450 mg/d or 600 mg/d) with food versus 750-mg/d fasted in patients with ALK receptor tyrosine kinase (ALK)-Positive NSCLC: primary efficacy results from the ASCEND-8 study (2019)
Cho, Byoung Chul; Obermannova, Radka; Bearz, Alessandra; Mckeage, Mark; Kim, Dong-Wang; Batra, Ullas; Borra, Gloria; Orlov, Sergey; Kim, Sang-We; Castro Junior, Gilberto de
Fonte: Journal of thoracic oncology. Unidade: FM
Assuntos: NEOPLASIAS PULMONARES, PROTEÍNAS QUINASES, JEJUM, ALIMENTOS, GASTROENTEROPATIAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
CHO, Byoung Chul et al. Efficacy and safety of ceritinib (450 mg/d or 600 mg/d) with food versus 750-mg/d fasted in patients with ALK receptor tyrosine kinase (ALK)-Positive NSCLC: primary efficacy results from the ASCEND-8 study. Journal of thoracic oncology, v. 14, n. 7, p. 1255-1265, 2019Tradução . . Disponível em: https://doi.org/10.1016/j.jtho.2019.03.002. Acesso em: 15 jun. 2025.
APA
Cho, B. C., Obermannova, R., Bearz, A., Mckeage, M., Kim, D. -W., Batra, U., et al. (2019). Efficacy and safety of ceritinib (450 mg/d or 600 mg/d) with food versus 750-mg/d fasted in patients with ALK receptor tyrosine kinase (ALK)-Positive NSCLC: primary efficacy results from the ASCEND-8 study. Journal of thoracic oncology, 14( 7), 1255-1265. doi:10.1016/j.jtho.2019.03.002
NLM
Cho BC, Obermannova R, Bearz A, Mckeage M, Kim D-W, Batra U, Borra G, Orlov S, Kim S-W, Castro Junior G de. Efficacy and safety of ceritinib (450 mg/d or 600 mg/d) with food versus 750-mg/d fasted in patients with ALK receptor tyrosine kinase (ALK)-Positive NSCLC: primary efficacy results from the ASCEND-8 study [Internet]. Journal of thoracic oncology. 2019 ; 14( 7): 1255-1265.[citado 2025 jun. 15 ] Available from: https://doi.org/10.1016/j.jtho.2019.03.002
Vancouver
Cho BC, Obermannova R, Bearz A, Mckeage M, Kim D-W, Batra U, Borra G, Orlov S, Kim S-W, Castro Junior G de. Efficacy and safety of ceritinib (450 mg/d or 600 mg/d) with food versus 750-mg/d fasted in patients with ALK receptor tyrosine kinase (ALK)-Positive NSCLC: primary efficacy results from the ASCEND-8 study [Internet]. Journal of thoracic oncology. 2019 ; 14( 7): 1255-1265.[citado 2025 jun. 15 ] Available from: https://doi.org/10.1016/j.jtho.2019.03.002
Trabalho de evento-resumo periodico
Clinical relevant oncogenic drivers in advanced adenocarcinoma discloses new therapeutic target in negative EGFR/ALK/KRAS patients (2017)
Machado, Juliana; Nagai, Maria Aparecida; Fabro, Alexandre Todorovic; Capelozzi, Vera Luiza
Fonte: Journal of thoracic oncology. Nome do evento: World conference on lun cancer - ASLC. Unidades: FM, FMRP
Assuntos: NEOPLASIAS PULMONARES, ADENOCARCINOMA, PULMÃO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
MACHADO, Juliana et al. Clinical relevant oncogenic drivers in advanced adenocarcinoma discloses new therapeutic target in negative EGFR/ALK/KRAS patients. Journal of thoracic oncology. New York: Faculdade de Medicina, Universidade de São Paulo. Disponível em: https://www.sciencedirect.com/journal/journal-of-thoracic-oncology/vol/12/issue/1/suppl/S. Acesso em: 15 jun. 2025. , 2017
APA
Machado, J., Nagai, M. A., Fabro, A. T., & Capelozzi, V. L. (2017). Clinical relevant oncogenic drivers in advanced adenocarcinoma discloses new therapeutic target in negative EGFR/ALK/KRAS patients. Journal of thoracic oncology. New York: Faculdade de Medicina, Universidade de São Paulo. Recuperado de https://www.sciencedirect.com/journal/journal-of-thoracic-oncology/vol/12/issue/1/suppl/S
NLM
Machado J, Nagai MA, Fabro AT, Capelozzi VL. Clinical relevant oncogenic drivers in advanced adenocarcinoma discloses new therapeutic target in negative EGFR/ALK/KRAS patients [Internet]. Journal of thoracic oncology. 2017 ; 12( 1): S955.[citado 2025 jun. 15 ] Available from: https://www.sciencedirect.com/journal/journal-of-thoracic-oncology/vol/12/issue/1/suppl/S
Vancouver
Machado J, Nagai MA, Fabro AT, Capelozzi VL. Clinical relevant oncogenic drivers in advanced adenocarcinoma discloses new therapeutic target in negative EGFR/ALK/KRAS patients [Internet]. Journal of thoracic oncology. 2017 ; 12( 1): S955.[citado 2025 jun. 15 ] Available from: https://www.sciencedirect.com/journal/journal-of-thoracic-oncology/vol/12/issue/1/suppl/S
Trabalho de evento-resumo periodico
Digital drainage system reduces chest tube duration and hospitalization after anatomic pulmonary resectios for malignancies (2017)
Araujo, Pedro; Vega, Alberto Dela; Laurecella, Letícia; Bibas, Benoit; Fernandes, Paulo Manuel Pego; Terra, Ricardo Mingarini
Fonte: Journal of thoracic oncology. Nome do evento: World conference on lun cancer - ASLC. Unidades: FM, FFLCH
Assuntos: NEOPLASIAS PULMONARES, PULMÃO, DRENAGEM
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
ARAUJO, Pedro et al. Digital drainage system reduces chest tube duration and hospitalization after anatomic pulmonary resectios for malignancies. Journal of thoracic oncology. New York: Faculdade de Medicina, Universidade de São Paulo. Disponível em: https://www.sciencedirect.com/journal/journal-of-thoracic-oncology/vol/12/issue/1/suppl/S. Acesso em: 15 jun. 2025. , 2017
APA
Araujo, P., Vega, A. D., Laurecella, L., Bibas, B., Fernandes, P. M. P., & Terra, R. M. (2017). Digital drainage system reduces chest tube duration and hospitalization after anatomic pulmonary resectios for malignancies. Journal of thoracic oncology. New York: Faculdade de Medicina, Universidade de São Paulo. Recuperado de https://www.sciencedirect.com/journal/journal-of-thoracic-oncology/vol/12/issue/1/suppl/S
NLM
Araujo P, Vega AD, Laurecella L, Bibas B, Fernandes PMP, Terra RM. Digital drainage system reduces chest tube duration and hospitalization after anatomic pulmonary resectios for malignancies [Internet]. Journal of thoracic oncology. 2017 ; 12( 1): S1403-S1404.[citado 2025 jun. 15 ] Available from: https://www.sciencedirect.com/journal/journal-of-thoracic-oncology/vol/12/issue/1/suppl/S
Vancouver
Araujo P, Vega AD, Laurecella L, Bibas B, Fernandes PMP, Terra RM. Digital drainage system reduces chest tube duration and hospitalization after anatomic pulmonary resectios for malignancies [Internet]. Journal of thoracic oncology. 2017 ; 12( 1): S1403-S1404.[citado 2025 jun. 15 ] Available from: https://www.sciencedirect.com/journal/journal-of-thoracic-oncology/vol/12/issue/1/suppl/S
Trabalho de evento-resumo periodico
Immunohistochemical assessment of biomarkers for immune checkpoint inhibitors (2017)
Capelozzi, Vera Luiza
Fonte: Journal of thoracic oncology. Nome do evento: World conference on lun cancer - ASLC. Unidade: FM
Assuntos: NEOPLASIAS PULMONARES, IMUNOTERAPIA, IMUNOHISTOQUÍMICA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
CAPELOZZI, Vera Luiza. Immunohistochemical assessment of biomarkers for immune checkpoint inhibitors. Journal of thoracic oncology. New York: Faculdade de Medicina, Universidade de São Paulo. Disponível em: https://doi.org/10.1016/j.jtho.2016.11.157. Acesso em: 15 jun. 2025. , 2017
APA
Capelozzi, V. L. (2017). Immunohistochemical assessment of biomarkers for immune checkpoint inhibitors. Journal of thoracic oncology. New York: Faculdade de Medicina, Universidade de São Paulo. doi:10.1016/j.jtho.2016.11.157
NLM
Capelozzi VL. Immunohistochemical assessment of biomarkers for immune checkpoint inhibitors [Internet]. Journal of thoracic oncology. 2017 ; 12( 1): S175-177.[citado 2025 jun. 15 ] Available from: https://doi.org/10.1016/j.jtho.2016.11.157
Vancouver
Capelozzi VL. Immunohistochemical assessment of biomarkers for immune checkpoint inhibitors [Internet]. Journal of thoracic oncology. 2017 ; 12( 1): S175-177.[citado 2025 jun. 15 ] Available from: https://doi.org/10.1016/j.jtho.2016.11.157
Trabalho de evento-resumo periodico
Anti-VEGF and Anti-EGFR Reduce Malignant Pleural Effusion and Morbidity in an Experimental Adenocarcinoma Model (2017)
Teixeira, Lisete; Acencio, Milena; Alvarenga, Vanessa; Silva, Gabriela; Brito, Zenaide; Fernezlian, Sandra; Puka, Juliana; Martins, Juliana; Capelozzi, Vera
Fonte: Journal of thoracic oncology. Nome do evento: World conference on lun cancer - ASLC. Unidade: FM
Assuntos: ADENOCARCINOMA, DERRAME PLEURAL, NEOPLASIAS PULMONARES
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
TEIXEIRA, Lisete et al. Anti-VEGF and Anti-EGFR Reduce Malignant Pleural Effusion and Morbidity in an Experimental Adenocarcinoma Model. Journal of thoracic oncology. New York: Faculdade de Medicina, Universidade de São Paulo. Disponível em: https://www.sciencedirect.com/journal/journal-of-thoracic-oncology/vol/12/issue/1/suppl/S. Acesso em: 15 jun. 2025. , 2017
APA
Teixeira, L., Acencio, M., Alvarenga, V., Silva, G., Brito, Z., Fernezlian, S., et al. (2017). Anti-VEGF and Anti-EGFR Reduce Malignant Pleural Effusion and Morbidity in an Experimental Adenocarcinoma Model. Journal of thoracic oncology. New York: Faculdade de Medicina, Universidade de São Paulo. Recuperado de https://www.sciencedirect.com/journal/journal-of-thoracic-oncology/vol/12/issue/1/suppl/S
NLM
Teixeira L, Acencio M, Alvarenga V, Silva G, Brito Z, Fernezlian S, Puka J, Martins J, Capelozzi V. Anti-VEGF and Anti-EGFR Reduce Malignant Pleural Effusion and Morbidity in an Experimental Adenocarcinoma Model [Internet]. Journal of thoracic oncology. 2017 ; 12( 1): S1276-S1277.[citado 2025 jun. 15 ] Available from: https://www.sciencedirect.com/journal/journal-of-thoracic-oncology/vol/12/issue/1/suppl/S
Vancouver
Teixeira L, Acencio M, Alvarenga V, Silva G, Brito Z, Fernezlian S, Puka J, Martins J, Capelozzi V. Anti-VEGF and Anti-EGFR Reduce Malignant Pleural Effusion and Morbidity in an Experimental Adenocarcinoma Model [Internet]. Journal of thoracic oncology. 2017 ; 12( 1): S1276-S1277.[citado 2025 jun. 15 ] Available from: https://www.sciencedirect.com/journal/journal-of-thoracic-oncology/vol/12/issue/1/suppl/S
Trabalho de evento-resumo periodico
Differences between pleurodesis using talc and silver nitrate at differente times of pleural disease in mice (2017)
Sabbion, Rodrigo; Terra, Ricardo Mingarini; Teixeira, Lisete Ribeiro; Bonizzio, Carolina; Acencio, Milena; Fernandes, Paulo Manuel Pego
Fonte: Journal of thoracic oncology. Nome do evento: World conference on lun cancer - ASLC. Unidade: FM
Assuntos: PLEURODESE, NITRATOS, RATOS, DERRAME PLEURAL MALIGNO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SABBION, Rodrigo et al. Differences between pleurodesis using talc and silver nitrate at differente times of pleural disease in mice. Journal of thoracic oncology. New York: Faculdade de Medicina, Universidade de São Paulo. Disponível em: https://www.sciencedirect.com/journal/journal-of-thoracic-oncology/vol/12/issue/1/suppl/S. Acesso em: 15 jun. 2025. , 2017
APA
Sabbion, R., Terra, R. M., Teixeira, L. R., Bonizzio, C., Acencio, M., & Fernandes, P. M. P. (2017). Differences between pleurodesis using talc and silver nitrate at differente times of pleural disease in mice. Journal of thoracic oncology. New York: Faculdade de Medicina, Universidade de São Paulo. Recuperado de https://www.sciencedirect.com/journal/journal-of-thoracic-oncology/vol/12/issue/1/suppl/S
NLM
Sabbion R, Terra RM, Teixeira LR, Bonizzio C, Acencio M, Fernandes PMP. Differences between pleurodesis using talc and silver nitrate at differente times of pleural disease in mice [Internet]. Journal of thoracic oncology. 2017 ; 12( 1): S1276-S1277.[citado 2025 jun. 15 ] Available from: https://www.sciencedirect.com/journal/journal-of-thoracic-oncology/vol/12/issue/1/suppl/S
Vancouver
Sabbion R, Terra RM, Teixeira LR, Bonizzio C, Acencio M, Fernandes PMP. Differences between pleurodesis using talc and silver nitrate at differente times of pleural disease in mice [Internet]. Journal of thoracic oncology. 2017 ; 12( 1): S1276-S1277.[citado 2025 jun. 15 ] Available from: https://www.sciencedirect.com/journal/journal-of-thoracic-oncology/vol/12/issue/1/suppl/S
Artigo de periodico
The IASLC Lung Cancer Staging Project: External Validation of the Revision of the TNM Stage Groupings in the Eighth Edition of the TNM Classification of Lung Cancer (2017)
Chansky, Kari; Detterbeck, Frank C; Nicholson, Andrew G; Rusch, Valerie W; Vallieres, Eric; Kennedy, Catherine; Krasnik, Mark; Peake, Michael; Terra, Ricardo Mingarini
Fonte: Journal of thoracic oncology. Unidade: FM
Assuntos: NEOPLASIAS PULMONARES, BANCO DE DADOS, ESTADIAMENTO DE NEOPLASIAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
CHANSKY, Kari et al. The IASLC Lung Cancer Staging Project: External Validation of the Revision of the TNM Stage Groupings in the Eighth Edition of the TNM Classification of Lung Cancer. Journal of thoracic oncology, v. 12, n. 7, p. 1109-1121, 2017Tradução . . Disponível em: https://doi.org/10.1016/j.jtho.2017.04.011. Acesso em: 15 jun. 2025.
APA
Chansky, K., Detterbeck, F. C., Nicholson, A. G., Rusch, V. W., Vallieres, E., Kennedy, C., et al. (2017). The IASLC Lung Cancer Staging Project: External Validation of the Revision of the TNM Stage Groupings in the Eighth Edition of the TNM Classification of Lung Cancer. Journal of thoracic oncology, 12( 7), 1109-1121. doi:10.1016/j.jtho.2017.04.011
NLM
Chansky K, Detterbeck FC, Nicholson AG, Rusch VW, Vallieres E, Kennedy C, Krasnik M, Peake M, Terra RM. The IASLC Lung Cancer Staging Project: External Validation of the Revision of the TNM Stage Groupings in the Eighth Edition of the TNM Classification of Lung Cancer [Internet]. Journal of thoracic oncology. 2017 ; 12( 7): 1109-1121.[citado 2025 jun. 15 ] Available from: https://doi.org/10.1016/j.jtho.2017.04.011
Vancouver
Chansky K, Detterbeck FC, Nicholson AG, Rusch VW, Vallieres E, Kennedy C, Krasnik M, Peake M, Terra RM. The IASLC Lung Cancer Staging Project: External Validation of the Revision of the TNM Stage Groupings in the Eighth Edition of the TNM Classification of Lung Cancer [Internet]. Journal of thoracic oncology. 2017 ; 12( 7): 1109-1121.[citado 2025 jun. 15 ] Available from: https://doi.org/10.1016/j.jtho.2017.04.011
Trabalho de evento-resumo periodico
13-gene signature of EMT reveals impact on invasion and metastasis of neuroendocrine carcinomas of the lung: a preliminary study (2017)
Prieto, Tabatha; Sá, Vanessa; Olivieri, Eloisa Helena Ribeiro; Silva, Eduardo da; Reis, Rui; Carraro, Dirce; Capelozzi, Vera Luiza
Fonte: Journal of thoracic oncology. Nome do evento: World conference on lun cancer - ASLC. Unidade: FM
Assuntos: NEOPLASIAS PULMONARES, METÁSTASE NEOPLÁSICA, CARCINOMA NEUROENDÓCRINO, CÉLULAS EPITELIAIS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
PRIETO, Tabatha et al. 13-gene signature of EMT reveals impact on invasion and metastasis of neuroendocrine carcinomas of the lung: a preliminary study. Journal of thoracic oncology. New York: Faculdade de Medicina, Universidade de São Paulo. Disponível em: https://doi.org/10.1016/j.jtho.2016.11.939. Acesso em: 15 jun. 2025. , 2017
APA
Prieto, T., Sá, V., Olivieri, E. H. R., Silva, E. da, Reis, R., Carraro, D., & Capelozzi, V. L. (2017). 13-gene signature of EMT reveals impact on invasion and metastasis of neuroendocrine carcinomas of the lung: a preliminary study. Journal of thoracic oncology. New York: Faculdade de Medicina, Universidade de São Paulo. doi:10.1016/j.jtho.2016.11.939
NLM
Prieto T, Sá V, Olivieri EHR, Silva E da, Reis R, Carraro D, Capelozzi VL. 13-gene signature of EMT reveals impact on invasion and metastasis of neuroendocrine carcinomas of the lung: a preliminary study [Internet]. Journal of thoracic oncology. 2017 ; 12( 1): S712-S713.[citado 2025 jun. 15 ] Available from: https://doi.org/10.1016/j.jtho.2016.11.939
Vancouver
Prieto T, Sá V, Olivieri EHR, Silva E da, Reis R, Carraro D, Capelozzi VL. 13-gene signature of EMT reveals impact on invasion and metastasis of neuroendocrine carcinomas of the lung: a preliminary study [Internet]. Journal of thoracic oncology. 2017 ; 12( 1): S712-S713.[citado 2025 jun. 15 ] Available from: https://doi.org/10.1016/j.jtho.2016.11.939
Trabalho de evento-resumo periodico
Gene signature of EMT in neuroendocrine lung carcinoma: a comparative analysis with adenocarcinoma and squamous cell carcinoma (2017)
Prieto, Tabatha; Sá, Vanessa de; Olivieri, Eloisa Helena Ribeiro; Silva, Eduardo da; Reis, Rui; Carraro, Dirce; Capelozzi, Vera Luiza
Fonte: Journal of thoracic oncology. Nome do evento: World conference on lun cancer - ASLC. Unidade: FM
Assuntos: METÁSTASE NEOPLÁSICA, ADENOCARCINOMA, CARCINOMA NEUROENDÓCRINO, NEOPLASIAS PULMONARES
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
PRIETO, Tabatha et al. Gene signature of EMT in neuroendocrine lung carcinoma: a comparative analysis with adenocarcinoma and squamous cell carcinoma. Journal of thoracic oncology. New York: Faculdade de Medicina, Universidade de São Paulo. Disponível em: https://www.sciencedirect.com/journal/journal-of-thoracic-oncology/vol/12/issue/1/suppl/S. Acesso em: 15 jun. 2025. , 2017
APA
Prieto, T., Sá, V. de, Olivieri, E. H. R., Silva, E. da, Reis, R., Carraro, D., & Capelozzi, V. L. (2017). Gene signature of EMT in neuroendocrine lung carcinoma: a comparative analysis with adenocarcinoma and squamous cell carcinoma. Journal of thoracic oncology. New York: Faculdade de Medicina, Universidade de São Paulo. Recuperado de https://www.sciencedirect.com/journal/journal-of-thoracic-oncology/vol/12/issue/1/suppl/S
NLM
Prieto T, Sá V de, Olivieri EHR, Silva E da, Reis R, Carraro D, Capelozzi VL. Gene signature of EMT in neuroendocrine lung carcinoma: a comparative analysis with adenocarcinoma and squamous cell carcinoma [Internet]. Journal of thoracic oncology. 2017 ; 12( 1): S714-S715.[citado 2025 jun. 15 ] Available from: https://www.sciencedirect.com/journal/journal-of-thoracic-oncology/vol/12/issue/1/suppl/S
Vancouver
Prieto T, Sá V de, Olivieri EHR, Silva E da, Reis R, Carraro D, Capelozzi VL. Gene signature of EMT in neuroendocrine lung carcinoma: a comparative analysis with adenocarcinoma and squamous cell carcinoma [Internet]. Journal of thoracic oncology. 2017 ; 12( 1): S714-S715.[citado 2025 jun. 15 ] Available from: https://www.sciencedirect.com/journal/journal-of-thoracic-oncology/vol/12/issue/1/suppl/S
Trabalho de evento-resumo periodico
Pequi fruit (Caryocar Brasiliense Camb) protects against oxidative stress induced by urethane in a experimental model of lung cancer (2013)
Colombo, Natalia; Parra, Edwin R.; Gelain, Daniel P.; Schnorr, Carlos E.; Kolling, Eduardo; Grisólia, César K.; Hage, Marcia; Barbeiro, Denise F.; Capelozzi, Vera L.
Fonte: Journal of thoracic oncology. Nome do evento: World Conference on Lung Cancer. Unidade: FM
Assuntos: NEOPLASIAS PULMONARES (TERAPIA), MODELOS ANIMAIS, PLANTAS MEDICINAIS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
COLOMBO, Natalia et al. Pequi fruit (Caryocar Brasiliense Camb) protects against oxidative stress induced by urethane in a experimental model of lung cancer. Journal of thoracic oncology. [S.l.]: Faculdade de Medicina, Universidade de São Paulo. . Acesso em: 15 jun. 2025. , 2013
APA
Colombo, N., Parra, E. R., Gelain, D. P., Schnorr, C. E., Kolling, E., Grisólia, C. K., et al. (2013). Pequi fruit (Caryocar Brasiliense Camb) protects against oxidative stress induced by urethane in a experimental model of lung cancer. Journal of thoracic oncology. Faculdade de Medicina, Universidade de São Paulo.
NLM
Colombo N, Parra ER, Gelain DP, Schnorr CE, Kolling E, Grisólia CK, Hage M, Barbeiro DF, Capelozzi VL. Pequi fruit (Caryocar Brasiliense Camb) protects against oxidative stress induced by urethane in a experimental model of lung cancer. Journal of thoracic oncology. 2013 ; 8 S742-S743.[citado 2025 jun. 15 ]
Vancouver
Colombo N, Parra ER, Gelain DP, Schnorr CE, Kolling E, Grisólia CK, Hage M, Barbeiro DF, Capelozzi VL. Pequi fruit (Caryocar Brasiliense Camb) protects against oxidative stress induced by urethane in a experimental model of lung cancer. Journal of thoracic oncology. 2013 ; 8 S742-S743.[citado 2025 jun. 15 ]
Trabalho de evento-resumo periodico
Erlotinib in metastatic pulmonary adenocarcinomas harbouring EGFR activating mutations, in Sao Paulo - Brazil (2013)
Caires-Lima, Rafael; Protasio, Bruno M.; Takahashi, Tiago K.; Mak, Milena P.; Nakazato, Denyei; Mesquita, Cristiane S.; Takagaki, Teresa Y.; Soares, Iberê C.; Mello, Evandro S.; Hoff, Paulo M.; Alves, Venâncio A.; Castro Jr., Gilberto
Fonte: Journal of thoracic oncology. Nome do evento: World Conference on Lung Cancer. Unidade: FM
Assuntos: NEOPLASIAS PULMONARES, POLIMORFISMO, ADENOCARCINOMA, MUTAÇÃO, METÁSTASE NEOPLÁSICA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
CAIRES-LIMA, Rafael et al. Erlotinib in metastatic pulmonary adenocarcinomas harbouring EGFR activating mutations, in Sao Paulo - Brazil. Journal of thoracic oncology. [S.l.]: Faculdade de Medicina, Universidade de São Paulo. . Acesso em: 15 jun. 2025. , 2013
APA
Caires-Lima, R., Protasio, B. M., Takahashi, T. K., Mak, M. P., Nakazato, D., Mesquita, C. S., et al. (2013). Erlotinib in metastatic pulmonary adenocarcinomas harbouring EGFR activating mutations, in Sao Paulo - Brazil. Journal of thoracic oncology. Faculdade de Medicina, Universidade de São Paulo.
NLM
Caires-Lima R, Protasio BM, Takahashi TK, Mak MP, Nakazato D, Mesquita CS, Takagaki TY, Soares IC, Mello ES, Hoff PM, Alves VA, Castro Jr. G. Erlotinib in metastatic pulmonary adenocarcinomas harbouring EGFR activating mutations, in Sao Paulo - Brazil. Journal of thoracic oncology. 2013 ; 8 S892.[citado 2025 jun. 15 ]
Vancouver
Caires-Lima R, Protasio BM, Takahashi TK, Mak MP, Nakazato D, Mesquita CS, Takagaki TY, Soares IC, Mello ES, Hoff PM, Alves VA, Castro Jr. G. Erlotinib in metastatic pulmonary adenocarcinomas harbouring EGFR activating mutations, in Sao Paulo - Brazil. Journal of thoracic oncology. 2013 ; 8 S892.[citado 2025 jun. 15 ]
Trabalho de evento-resumo periodico
Malignant pleural mesothelioma: accumulated experience in a brazilian teritary hospital (2013)
Bibas, Benoit J.; Terra, Ricardo M.; Tamagno, Mauro F. L.; Beyruti, Ricardo; Pêgo-Fernandes, Paulo M.
Fonte: Journal of thoracic oncology. Nome do evento: World Conference on Lung Cancer. Unidade: FM
Assuntos: PLEURA (PATOLOGIA;HISTOPATOLOGIA), SOBREVIDA, NEOPLASIAS PULMONARES, QUIMIOTERÁPICOS (CLASSIFICAÇÃO)
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
BIBAS, Benoit J. et al. Malignant pleural mesothelioma: accumulated experience in a brazilian teritary hospital. Journal of thoracic oncology. [S.l.]: Faculdade de Medicina, Universidade de São Paulo. . Acesso em: 15 jun. 2025. , 2013
APA
Bibas, B. J., Terra, R. M., Tamagno, M. F. L., Beyruti, R., & Pêgo-Fernandes, P. M. (2013). Malignant pleural mesothelioma: accumulated experience in a brazilian teritary hospital. Journal of thoracic oncology. Faculdade de Medicina, Universidade de São Paulo.
NLM
Bibas BJ, Terra RM, Tamagno MFL, Beyruti R, Pêgo-Fernandes PM. Malignant pleural mesothelioma: accumulated experience in a brazilian teritary hospital. Journal of thoracic oncology. 2013 ; 8 S1319.[citado 2025 jun. 15 ]
Vancouver
Bibas BJ, Terra RM, Tamagno MFL, Beyruti R, Pêgo-Fernandes PM. Malignant pleural mesothelioma: accumulated experience in a brazilian teritary hospital. Journal of thoracic oncology. 2013 ; 8 S1319.[citado 2025 jun. 15 ]
Trabalho de evento-resumo periodico
Iodopovidone for pleurodesis in patients with malignant pleural effusion: a safe option (2013)
Neto, José D. A.; Terra, Ricardo M.; Vianna, Silvana; Maia, Rodrigo; Mariani, Alessandro W.; Pêgo-Fernandes, Paulo M.
Fonte: Journal of thoracic oncology. Nome do evento: World Conference on Lung Cancer. Unidade: FM
Assuntos: PLEURA (FISIOPATOLOGIA), PLEURODESE, ANTIBIÓTICOS, EVENTO ADVERSO A MEDICAMENTO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
NETO, José D. A. et al. Iodopovidone for pleurodesis in patients with malignant pleural effusion: a safe option. Journal of thoracic oncology. [S.l.]: Faculdade de Medicina, Universidade de São Paulo. . Acesso em: 15 jun. 2025. , 2013
APA
Neto, J. D. A., Terra, R. M., Vianna, S., Maia, R., Mariani, A. W., & Pêgo-Fernandes, P. M. (2013). Iodopovidone for pleurodesis in patients with malignant pleural effusion: a safe option. Journal of thoracic oncology. Faculdade de Medicina, Universidade de São Paulo.
NLM
Neto JDA, Terra RM, Vianna S, Maia R, Mariani AW, Pêgo-Fernandes PM. Iodopovidone for pleurodesis in patients with malignant pleural effusion: a safe option. Journal of thoracic oncology. 2013 ; 8 S1319.[citado 2025 jun. 15 ]
Vancouver
Neto JDA, Terra RM, Vianna S, Maia R, Mariani AW, Pêgo-Fernandes PM. Iodopovidone for pleurodesis in patients with malignant pleural effusion: a safe option. Journal of thoracic oncology. 2013 ; 8 S1319.[citado 2025 jun. 15 ]
Trabalho de evento-resumo periodico
Pleural fluid ADA is associated with survival of patients with malignant pleural effusion (2013)
Terra, Ricardo M.; Mariani, Alessandro W.; Antonangelo, Leila; Suesada, Milena M.; Pêgo-Fernandes, Paulo M.
Fonte: Journal of thoracic oncology. Nome do evento: World Conference on Lung Cancer. Unidade: FM
Assuntos: PLEURA (PATOLOGIA), PLEURODESE, ESTUDOS RETROSPECTIVOS, NEOPLASIAS (MORTALIDADE)
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
TERRA, Ricardo M. et al. Pleural fluid ADA is associated with survival of patients with malignant pleural effusion. Journal of thoracic oncology. [S.l.]: Faculdade de Medicina, Universidade de São Paulo. . Acesso em: 15 jun. 2025. , 2013
APA
Terra, R. M., Mariani, A. W., Antonangelo, L., Suesada, M. M., & Pêgo-Fernandes, P. M. (2013). Pleural fluid ADA is associated with survival of patients with malignant pleural effusion. Journal of thoracic oncology. Faculdade de Medicina, Universidade de São Paulo.
NLM
Terra RM, Mariani AW, Antonangelo L, Suesada MM, Pêgo-Fernandes PM. Pleural fluid ADA is associated with survival of patients with malignant pleural effusion. Journal of thoracic oncology. 2013 ; 8 S1093.[citado 2025 jun. 15 ]
Vancouver
Terra RM, Mariani AW, Antonangelo L, Suesada MM, Pêgo-Fernandes PM. Pleural fluid ADA is associated with survival of patients with malignant pleural effusion. Journal of thoracic oncology. 2013 ; 8 S1093.[citado 2025 jun. 15 ]
Trabalho de evento-resumo periodico
Primary thoracic angiosarcoma: treatment and outcomes of 5 patients (2013)
Scaranti, Mariana; Yen, Cheng T.; De Oliveira, Julia A.; Toloi, Diego A.; Siqueira, Sheila A. C.; Martins, Renata E.; De Camargo, Veridiana P.; Feher, Olavo; Hoff, Paulo M.; Castro Jr., Gilberto
Fonte: Journal of thoracic oncology. Nome do evento: World Conference on Lung Cancer. Unidade: FM
Assuntos: NEOPLASIAS ABDOMINAIS (TERAPIA;DIAGNÓSTICO), SARCOMA (TERAPIA), PROGNÓSTICO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SCARANTI, Mariana et al. Primary thoracic angiosarcoma: treatment and outcomes of 5 patients. Journal of thoracic oncology. [S.l.]: Faculdade de Medicina, Universidade de São Paulo. . Acesso em: 15 jun. 2025. , 2013
APA
Scaranti, M., Yen, C. T., De Oliveira, J. A., Toloi, D. A., Siqueira, S. A. C., Martins, R. E., et al. (2013). Primary thoracic angiosarcoma: treatment and outcomes of 5 patients. Journal of thoracic oncology. Faculdade de Medicina, Universidade de São Paulo.
NLM
Scaranti M, Yen CT, De Oliveira JA, Toloi DA, Siqueira SAC, Martins RE, De Camargo VP, Feher O, Hoff PM, Castro Jr. G. Primary thoracic angiosarcoma: treatment and outcomes of 5 patients. Journal of thoracic oncology. 2013 ; 8 S1325.[citado 2025 jun. 15 ]
Vancouver
Scaranti M, Yen CT, De Oliveira JA, Toloi DA, Siqueira SAC, Martins RE, De Camargo VP, Feher O, Hoff PM, Castro Jr. G. Primary thoracic angiosarcoma: treatment and outcomes of 5 patients. Journal of thoracic oncology. 2013 ; 8 S1325.[citado 2025 jun. 15 ]
Trabalho de evento-resumo periodico
Epidermal growth factor receptor mutations in primary and metastatic adenocarcinomas from a tertiary hospital in Sao Paulo, Brazil (2013)
De Sa, Vanessa K.; Nascimento, Ellen C.; Meireles, Sibele I.; Capelozzi, Vera L.
Fonte: Journal of thoracic oncology. Nome do evento: World Conference on Lung Cancer. Unidade: FM
Assuntos: ADENOCARCINOMA, PROGNÓSTICO, MUTAÇÃO GENÉTICA, TABAGISMO (COMPLICAÇÕES)
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
DE SA, Vanessa K. et al. Epidermal growth factor receptor mutations in primary and metastatic adenocarcinomas from a tertiary hospital in Sao Paulo, Brazil. Journal of thoracic oncology. [S.l.]: Faculdade de Medicina, Universidade de São Paulo. . Acesso em: 15 jun. 2025. , 2013
APA
De Sa, V. K., Nascimento, E. C., Meireles, S. I., & Capelozzi, V. L. (2013). Epidermal growth factor receptor mutations in primary and metastatic adenocarcinomas from a tertiary hospital in Sao Paulo, Brazil. Journal of thoracic oncology. Faculdade de Medicina, Universidade de São Paulo.
NLM
De Sa VK, Nascimento EC, Meireles SI, Capelozzi VL. Epidermal growth factor receptor mutations in primary and metastatic adenocarcinomas from a tertiary hospital in Sao Paulo, Brazil. Journal of thoracic oncology. 2013 ; 8 S660.[citado 2025 jun. 15 ]
Vancouver
De Sa VK, Nascimento EC, Meireles SI, Capelozzi VL. Epidermal growth factor receptor mutations in primary and metastatic adenocarcinomas from a tertiary hospital in Sao Paulo, Brazil. Journal of thoracic oncology. 2013 ; 8 S660.[citado 2025 jun. 15 ]
Trabalho de evento-resumo periodico
Quality of life in patients with malignant pleural effusion undergoing pleurodesi (2013)
Terra, Ricardo M.; Mariani, Alessandro W.; Neto, José D. A.; Suesada, Milena M.; Pêgo-Fernandes, Paulo M.
Fonte: Journal of thoracic oncology. Nome do evento: World Conference on Lung Cancer. Unidade: FM
Assuntos: TERAPIA RESPIRATÓRIA, PLEURODESE, QUALIDADE DE VIDA, CUIDADOS PALIATIVOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
TERRA, Ricardo M. et al. Quality of life in patients with malignant pleural effusion undergoing pleurodesi. Journal of thoracic oncology. [S.l.]: Faculdade de Medicina, Universidade de São Paulo. . Acesso em: 15 jun. 2025. , 2013
APA
Terra, R. M., Mariani, A. W., Neto, J. D. A., Suesada, M. M., & Pêgo-Fernandes, P. M. (2013). Quality of life in patients with malignant pleural effusion undergoing pleurodesi. Journal of thoracic oncology. Faculdade de Medicina, Universidade de São Paulo.
NLM
Terra RM, Mariani AW, Neto JDA, Suesada MM, Pêgo-Fernandes PM. Quality of life in patients with malignant pleural effusion undergoing pleurodesi. Journal of thoracic oncology. 2013 ; 8 S1022.[citado 2025 jun. 15 ]
Vancouver
Terra RM, Mariani AW, Neto JDA, Suesada MM, Pêgo-Fernandes PM. Quality of life in patients with malignant pleural effusion undergoing pleurodesi. Journal of thoracic oncology. 2013 ; 8 S1022.[citado 2025 jun. 15 ]
Trabalho de evento-resumo periodico
Polymorphisms in the exon 20 of EGFR gene in metastatic lung adenocarcinoma: prognostic relevance and sensitivity to erlotinib (2013)
Castro Jr., Gilberto; Soares, Iberê C.; Takahashi, Tiago K.; Maia, Manuel C. D. F.; Caires-Lima, Rafael; Protasio, Bruno M.; Takagaki, Teresa Y.; Shiang, Christina; Mello, Evandro S.; Hoff, Paulo M.; Alves, Venâncio A.
Fonte: Journal of thoracic oncology. Nome do evento: World Conference on Lung Cancer. Unidade: FM
Assuntos: NEOPLASIAS PULMONARES, POLIMORFISMO, ADENOCARCINOMA, TÉCNICAS CITOLÓGICAS (TENDÊNCIAS)
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
CASTRO JR., Gilberto et al. Polymorphisms in the exon 20 of EGFR gene in metastatic lung adenocarcinoma: prognostic relevance and sensitivity to erlotinib. Journal of thoracic oncology. [S.l.]: Faculdade de Medicina, Universidade de São Paulo. . Acesso em: 15 jun. 2025. , 2013
APA
Castro Jr., G., Soares, I. C., Takahashi, T. K., Maia, M. C. D. F., Caires-Lima, R., Protasio, B. M., et al. (2013). Polymorphisms in the exon 20 of EGFR gene in metastatic lung adenocarcinoma: prognostic relevance and sensitivity to erlotinib. Journal of thoracic oncology. Faculdade de Medicina, Universidade de São Paulo.
NLM
Castro Jr. G, Soares IC, Takahashi TK, Maia MCDF, Caires-Lima R, Protasio BM, Takagaki TY, Shiang C, Mello ES, Hoff PM, Alves VA. Polymorphisms in the exon 20 of EGFR gene in metastatic lung adenocarcinoma: prognostic relevance and sensitivity to erlotinib. Journal of thoracic oncology. 2013 ; 8 S784.[citado 2025 jun. 15 ]
Vancouver
Castro Jr. G, Soares IC, Takahashi TK, Maia MCDF, Caires-Lima R, Protasio BM, Takagaki TY, Shiang C, Mello ES, Hoff PM, Alves VA. Polymorphisms in the exon 20 of EGFR gene in metastatic lung adenocarcinoma: prognostic relevance and sensitivity to erlotinib. Journal of thoracic oncology. 2013 ; 8 S784.[citado 2025 jun. 15 ]

Unidades USP

ReP

Filtros

Departamento

Autores

Autores USP

Assuntos